PA8855001A1 - Monocarbamas - Google Patents

Monocarbamas

Info

Publication number
PA8855001A1
PA8855001A1 PA20098855001A PA8855001A PA8855001A1 PA 8855001 A1 PA8855001 A1 PA 8855001A1 PA 20098855001 A PA20098855001 A PA 20098855001A PA 8855001 A PA8855001 A PA 8855001A PA 8855001 A1 PA8855001 A1 PA 8855001A1
Authority
PA
Panama
Prior art keywords
monocarbamas
compounds
formula
refers
memory
Prior art date
Application number
PA20098855001A
Other languages
English (en)
Spanish (es)
Inventor
Singh Lall Manjinder
Edward Flanagan Mark
Joseph Brickner Steven
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8855001A1 publication Critical patent/PA8855001A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
PA20098855001A 2008-12-19 2009-12-18 Monocarbamas PA8855001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13915908P 2008-12-19 2008-12-19

Publications (1)

Publication Number Publication Date
PA8855001A1 true PA8855001A1 (es) 2010-07-27

Family

ID=41727494

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098855001A PA8855001A1 (es) 2008-12-19 2009-12-18 Monocarbamas

Country Status (15)

Country Link
US (2) US8252782B2 (pt-PT)
EP (1) EP2379546A1 (pt-PT)
JP (1) JP2012512863A (pt-PT)
KR (1) KR20110086742A (pt-PT)
CN (1) CN102325769A (pt-PT)
AR (1) AR074801A1 (pt-PT)
AU (1) AU2009329169B2 (pt-PT)
CA (1) CA2744756C (pt-PT)
IL (1) IL213216A0 (pt-PT)
MX (1) MX2011006541A (pt-PT)
PA (1) PA8855001A1 (pt-PT)
SG (1) SG171781A1 (pt-PT)
TW (1) TW201026696A (pt-PT)
UY (1) UY32336A (pt-PT)
WO (1) WO2010070523A1 (pt-PT)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102325769A (zh) * 2008-12-19 2012-01-18 美国辉瑞有限公司 单卡波姆
DK2646436T3 (en) * 2010-11-29 2015-06-29 Pfizer monobactams
UY34585A (es) * 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
EA037569B1 (ru) * 2015-09-23 2021-04-15 Новартис Аг Соли монобактамного антибиотика и их применение
CN105481812B (zh) * 2015-11-30 2020-04-21 重庆天奕恒化科技有限公司 一种5-苄氧基-4-氧代-4h-吡喃-2-羧酸的制备方法
EP3558987A1 (en) 2016-12-21 2019-10-30 AiCuris GmbH & Co. KG COMBINATION THERAPY WITH AMIDINE SUBSTITUTED ß-LACTAM COMPOUNDS AND ß-LACTAMASE INHIBITORS FOR INFECTIONS WITH ANTIBIOTIC RESISTANT BACTERIAL STRAINS
CN111094281B (zh) 2017-08-02 2023-08-29 诺华股份有限公司 用于制备单内酰胺抗生素的化学方法及其中间体
CN110997627B (zh) 2017-08-23 2023-10-10 亥姆霍兹感染研究中心有限公司 孢囊菌酰胺衍生物
BR112020004036A2 (pt) 2017-08-31 2020-09-01 Hokko Chemical Industry Co., Ltd derivado de 1-(n,n-carbamoíla dissubstituída) 4-(sulfonila substituída) triazolin-5-ona, derivado de 4-(n,n-carbamoíla dissubstituída) 1-(sulfonila substituída) triazolin-5-ona e herbicida contendo os mesmos como ingrediente ativo
EP3747883A4 (en) 2018-01-29 2020-12-16 Medshine Discovery Inc. B-LACTAM MONOCYCLIC COMPOUND FOR TREATMENT OF BACTERIAL INFECTION
EP4079305A4 (en) 2019-12-19 2024-01-10 Shenzhen Optimum Biological Technology Co., Ltd APPLICATION OF A COMPOUND IN THE PREPARATION OF DRUG

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199981A (en) 1981-04-09 1985-08-16 Squibb & Sons Inc 2-oxo-1-(((substituted sulphonyl)amino)carbonyl)azetidines
US4587047A (en) * 1981-04-09 1986-05-06 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
US5006650A (en) * 1987-02-11 1991-04-09 The Upjohn Company Novel N-1 substituted beta-lactams as antibiotics
EP0344197B1 (en) 1987-02-11 1991-08-14 The Upjohn Company Novel n-1 substituted beta-lactams as antibiotics
AU600094B2 (en) * 1987-02-27 1990-08-02 Upjohn Company, The Antibiotic 2- azetidinones have pyrid -4- one 2-yl- carbonylamino-1-imidazolid-2-one-3-yl sulfonylaminocarbonyl groups at N-1
CA1317298C (en) 1987-03-03 1993-05-04 Upjohn Company (The) Antibiotic sulfonylaminocarbonyl activated .beta.-lactams
US4762922A (en) * 1987-07-01 1988-08-09 Squibb Corporation 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
US5015737A (en) * 1987-07-22 1991-05-14 The Upjohn Company Therapeutically useful beta-lactams
US4777252A (en) 1987-08-13 1988-10-11 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
US4889930A (en) 1987-12-21 1989-12-26 E. R. Squibb & Sons, Inc. Process for making 2-oxo-1-((substituted sulfonyl)amino)carbonzyl)azetidines and intermediates used therein
JPH01305081A (ja) 1988-04-04 1989-12-08 E R Squibb & Sons Inc 3―アシルアミノ―1―[[[(置換スルホニル)アミノ〕カルボニル〕アミノ〕―2―アゼチジノン類
EP0344707A3 (en) 1988-06-02 1990-04-18 E.R. Squibb & Sons, Inc. 2-Oxo-1-[[(substituted sulfonyl)-amino]carbonyl]-azetidine derivatives
US4959470A (en) 1988-08-17 1990-09-25 E. R. Squibb & Sons, Inc. 2-oxo-[[(substituted sulfonyl)-amino]carbonyl]-azetidines
AU4064089A (en) 1988-09-27 1990-04-18 Upjohn Company, The Dihydroxyaryl 4-substituted monocarbams as antibiotics
CA2210787A1 (en) 1997-07-17 1999-01-17 William R. Collier Self-contained work station
MX2009009918A (es) 2007-03-23 2009-10-19 Basilea Pharmaceutica Ag Medicamentos combinados para el tratamiento de infecciones bacterianas.
CN102325769A (zh) * 2008-12-19 2012-01-18 美国辉瑞有限公司 单卡波姆

Also Published As

Publication number Publication date
CN102325769A (zh) 2012-01-18
US20100160281A1 (en) 2010-06-24
AU2009329169A1 (en) 2010-06-24
CA2744756C (en) 2013-05-28
US20120289455A1 (en) 2012-11-15
CA2744756A1 (en) 2010-06-24
US8324198B1 (en) 2012-12-04
SG171781A1 (en) 2011-07-28
AU2009329169B2 (en) 2012-06-28
JP2012512863A (ja) 2012-06-07
WO2010070523A1 (en) 2010-06-24
AR074801A1 (es) 2011-02-16
EP2379546A1 (en) 2011-10-26
MX2011006541A (es) 2011-07-20
IL213216A0 (en) 2011-07-31
TW201026696A (en) 2010-07-16
US8252782B2 (en) 2012-08-28
UY32336A (es) 2010-07-30
KR20110086742A (ko) 2011-07-29

Similar Documents

Publication Publication Date Title
PA8855001A1 (es) Monocarbamas
CY1118104T1 (el) Νεα κυτταροστατικα νουκλεοζιδια 7-αποαζαπουρινης
CR11861A (es) Compuestos organicos
SV2011003855A (es) Heteroarilos sustituidos
EA201170832A1 (ru) Пуриновые соединения
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
BRPI0818672A2 (pt) 2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase
UY31524A1 (es) Nuevos compuestos 010
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
EA201170772A1 (ru) Органические соединения
UA112428C2 (uk) Пестицидні композиції і пов'язані з ними способи
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
UA106880C2 (uk) Нові гербіциди
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
TN2011000355A1 (en) Novel microbiocides
CO6341625A2 (es) Derivados de indol como agentes anticáncer
DOP2009000214A (es) Macrolidos basados en eritromicina
UY33181A (es) Derivados de oxazolopirimidina 2,5-sustituidos.
IN2012DN01223A (pt-PT)
CL2008003928A1 (es) Compuestos derivados de n-6-heterociclo-imidazo-[1,2-a]-piridin-2-carboxamida sustituidos; procedimiento de preparacion; composicion farmaceutica; utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas, inflamatorias, epilepsia, osteoporosis, tumores malignos, entre otras.
UY32447A (es) Derivados de 3-benzofuranilindol-2-ona sustituidos en 3, su preparacion y su aplicacion en terapia